Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIa Vaccination Study.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Shigella flexneri vaccine CVD-1205 (Primary)
- Indications Shigella infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 29 Apr 2021 Biomarkers information updated
- 01 Apr 2010 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
- 04 Nov 2009 Planned initiation date changed from 1 Jun 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.